BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Raises Stake in Becton, Dickinson and Company (NYSE:BDX)

VaselineSeptember 25, 2024

0 4 minutes read

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 59.6% during the second quarter, Holdings Channel.com reports. The firm owned 55,331 shares of the medical instruments supplier’s stock after purchasing an additional 20,653 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Becton, Dickinson and Company were worth $12,931,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BDX. Nordea Investment Management AB boosted its stake in Becton, Dickinson and Company by 277.3% in the first quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after buying an additional 1,423,353 shares during the period. PineStone Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 141.6% during the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after purchasing an additional 788,735 shares in the last quarter. M&G Plc purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $173,692,000. First Eagle Investment Management LLC raised its position in shares of Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after acquiring an additional 688,296 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after acquiring an additional 346,720 shares in the last quarter. 86.97% of the shares are held by hedge funds and other institutional investors.

Becton, Dickinson and Company stocks rose 0.9%

Shares of BDX opened at $236.95 on Wednesday. The company has a fifty day moving average price of $235.81 and a 200 day moving average price of $235.49. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52. The company has a market cap of $68.48 billion, a price-to-earnings ratio of 52.19, a price-to-earnings-growth ratio of 1.91 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85, and a quick ratio of 1.36.

Want more great investment ideas?

Becton, Dickinson and Company (NYSE:BDX – Get Your Free Report ) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. In the same quarter last year, the firm earned $2.96 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. sell-side analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9. This represents an annualized dividend of $3.80 and a yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Analysts set new price targets

A number of brokerages have recently weighed in on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI cut their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target for the company. Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Finally, Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, the 26th July. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Moderate Buy” and a consensus price target of $279.50, according to MarketBeat.com.

Read our latest report on Becton, Dickinson and Company

Becton, Dickinson and company profile

(Free Report)

Becton, Dickinson and Company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences and BD Interventional.